AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26873040 — intervention group
Group type: COMPARATOR
Intervention: Short ITI (mean=30+/‐ 5s)
Number of subjects: 0
Study 26873040 — intervention group
Group type: COMPARATOR
Intervention: Long ITI (mean=57+/‐ 5s)
Number of subjects: 0
Study 26873040 — intervention group
Group type: COMPARATOR
Intervention: CS alone trials
Number of subjects: 0
Study 24879836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0
Study 24879836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0
Study 24879836 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg
Number of subjects: 0
Study 24879836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22229712 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg meperidine in 10 mL of saline (slow intravenous injection over 2 min)
Number of subjects: 240
Study 22229712 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of isotonic saline (control group)
Number of subjects: 240
Study 20822189 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted personalized drinking feedback (PDF) intervention
Number of subjects: 263
Study 20822189 — intervention group
Group type: COMPARATOR
Intervention: Standard (nontargeted) PDF intervention
Number of subjects: 263
Study 20822189 — intervention group
Group type: COMPARATOR
Intervention: Education-only (EO) condition
Number of subjects: 263
Study 16685506 — intervention group
Group type: EXPERIMENTAL
Intervention: Clo‐Sur PAD device (n=60)
Number of subjects: 120
Study 16685506 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (n=60)
Number of subjects: 120
Study 16240555 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral informant assessment
Number of subjects: 1264
Study 16240555 — intervention group
Group type: COMPARATOR
Intervention: Collateral verification
Number of subjects: 1264
Study 16240555 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral reports
Number of subjects: 1264
Study 16240555 — intervention group
Group type: EXPERIMENTAL
Intervention: Time and expense of collateral data collection
Number of subjects: 1264
Study 12006918 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele of the hepatic lipase -514 C/T polymorphism in male CHD subjects (n = 490)
Number of subjects: 562
Study 12006918 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele of the hepatic lipase -514 C/T polymorphism in male CHD subjects
Number of subjects: 562
Study 12006918 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele in male CHD patients
Number of subjects: 562
Study 12006918 — intervention group
Group type: COMPARATOR
Intervention: T homozygotes in community control subjects
Number of subjects: 562
Study 9706925 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle bevel directed cephalad (Group 90)
Number of subjects: 160
Study 9706925 — intervention group
Group type: COMPARATOR
Intervention: Needle bevel no rotation (Group 0)
Number of subjects: 160
Study 9706925 — intervention group
Group type: COMPARATOR
Intervention: Needle bevel rotated 180 degrees (Group 180)
Number of subjects: 160
Study 9706925 — intervention group
Group type: COMPARATOR
Intervention: Needle bevel rotated 270 degrees (Group 270)
Number of subjects: 160
Study 7881967 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IL-2
Number of subjects: 18
Study 7881967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2239141 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH treatment (100 units intramuscular, tapered over 12 weeks)
Number of subjects: 29
Study 626839 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0
Study 626839 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 31221615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytetracycline-impregnated gauze drain
Number of subjects: 200
Study 31221615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drain)
Number of subjects: 200
Study 28482993 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Teleconference Intervention
Number of subjects: 0
Study 26486190 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone therapy (0.625 mg/day conjugated equine estrogens with or without 2.5 mg/day medroxyprogesterone acetate)
Number of subjects: 7233
Study 26486190 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 7233
Study 23264012 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 105
Study 23264012 — intervention group
Group type: EXPERIMENTAL
Intervention: X-Lite video laryngoscope
Number of subjects: 105
Study 23264012 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope with Macintosh blade
Number of subjects: 105
Study 20080928 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained release 150 mg b.i.d. (n = 109)
Number of subjects: 218
Study 20080928 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 109)
Number of subjects: 218
Study 19207322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel with preincorporated lidocaine
Number of subjects: 60
Study 19207322 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid gel alone
Number of subjects: 60
Study 17995589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 21
Study 17995589 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 21
Study 15018852 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 750 mg once daily
Number of subjects: 559
Study 15018852 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg twice daily
Number of subjects: 559
Study 15018852 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg three times daily
Number of subjects: 559
Study 15018852 — intervention group
Group type: COMPARATOR
Intervention: Aciclovir 800 mg five times daily
Number of subjects: 559
Study 10639394 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 25
Study 9305331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (up to 4.5 mg/d, mean daily dose 3.8 mg during maintenance)
Number of subjects: 335
Study 9305331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 8349377 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg x 1
Number of subjects: 25
Study 8349377 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release diltiazem 120 mg x 2
Number of subjects: 25
Study 8349377 — intervention group
Group type: EXPERIMENTAL
Intervention: combination therapy (atenolol + diltiazem)
Number of subjects: 25
Study 8349377 — intervention group
Group type: COMPARATOR
Intervention: diltiazem
Number of subjects: 25
Study 3729382 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg
Number of subjects: 2
Study 3729382 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg
Number of subjects: 2
Study 3729382 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg
Number of subjects: 2
Study 3729382 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 2
Study 29496722 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg/day)
Number of subjects: 2058
Study 29496722 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D (1200 mg/day calcium and 1000 IU/day vitamin D3)
Number of subjects: 2058
Study 29496722 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alone
Number of subjects: 2058
Study 29496722 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D
Number of subjects: 2058
Study 27796666 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 63
Study 27796666 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 63
Study 26121546 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum chewing (mint-flavored, sugarless) starting 6 hours after surgery, chewed until flatus occurred thrice a day
Number of subjects: 120
Study 26121546 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative regimen (Control)
Number of subjects: 120
Study 23403425 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB)
Number of subjects: 106
Study 23403425 — intervention group
Group type: COMPARATOR
Intervention: Mupirocin
Number of subjects: 106
Study 21784047 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg daily for 4 months
Number of subjects: 55
Study 21784047 — intervention group
Group type: COMPARATOR
Intervention: Control group (400 mg iron daily for 4 months)
Number of subjects: 55
Study 19748846 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted letter
Number of subjects: 15000
Study 19748846 — intervention group
Group type: EXPERIMENTAL
Intervention: General reminder letter
Number of subjects: 15000
Study 19748846 — intervention group
Group type: COMPARATOR
Intervention: Control group (no letter)
Number of subjects: 15000
Study 16531616 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day)
Number of subjects: 15603
Study 16531616 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus low-dose aspirin
Number of subjects: 15603
Study 16531616 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 15603
Study 16531616 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 15603
Study 16531616 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 15603
Study 16531616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15603
Study 14744472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX) 20 mg/day
Number of subjects: 39
Study 14744472 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) adjusted to an adequate plasma level
Number of subjects: 39
Study 14744472 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FLX 20 mg/day and DMI
Number of subjects: 39
Study 11317830 — intervention group
Group type: EXPERIMENTAL
Intervention: Eupatorium laevigatum paste
Number of subjects: 60
Study 11317830 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone 0.1% orabase
Number of subjects: 60
Study 8695092 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium 75 micrograms/kg
Number of subjects: 20
Study 8695092 — intervention group
Group type: COMPARATOR
Intervention: Pipecuronium 123 micrograms/kg
Number of subjects: 20
Study 1474165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 200 mg oral dose during interdialytic period
Number of subjects: 6
Study 1474165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 200 mg oral dose during intradialytic period
Number of subjects: 6
Study 1474165 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis session
Number of subjects: 6
Study 1474165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime plasma concentration post-hemodialysis
Number of subjects: 6
Study 6151246 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality-adaptive, supportive (RAS) psychotherapy
Number of subjects: 95
Study 6151246 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory, insight-oriented (EIO) psychotherapy
Number of subjects: 95
Study 30634687 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurisolo® (grape pomace polyphenolic extract)
Number of subjects: 0
Study 30634687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28045338 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 61
Study 28045338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 27503237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fevipiprant (225 mg twice per day orally)
Number of subjects: 61
Study 27503237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 25326910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 392
Study 25326910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 25326910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and Placebo (combined analysis)
Number of subjects: 392
Study 22354133 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 10
Study 22354133 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 10
Study 22354133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20132916 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel Hemorrhoidectomy
Number of subjects: 0
Study 20132916 — intervention group
Group type: COMPARATOR
Intervention: Bipolar Electro‐cautery Hemorrhoidectomy
Number of subjects: 0
Study 17158592 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (ZD1839, Iressa)
Number of subjects: 0
Study 17158592 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (OSI-774, Tarceva)
Number of subjects: 0
Study 17158592 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic EGFR-activating mutations
Number of subjects: 0
Study 15899952 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at doses ranging from 0.18-0.37 mg/kg.wk
Number of subjects: 0
Study 15899952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in the placebo-controlled study)
Number of subjects: 0
Study 12153923 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor's readings
Number of subjects: 0
Study 12153923 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent clinic readings
Number of subjects: 0
Study 12153923 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor's readings in treated patients with poor control
Number of subjects: 0
Study 12153923 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated readings by nurse
Number of subjects: 0
Study 12153923 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated self measurement
Number of subjects: 0
Study 12153923 — intervention group
Group type: EXPERIMENTAL
Intervention: Home readings
Number of subjects: 0
Study 12153923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse readings
Number of subjects: 0
Study 12153923 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient in surgery readings
Number of subjects: 0
Study 9989408 — intervention group
Group type: EXPERIMENTAL
Intervention: Face perception
Number of subjects: 0
Study 9989408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from perception to motor response
Number of subjects: 0
Study 7498689 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate-based laxative (divided doses: 4 PM and 8 PM)
Number of subjects: 200
Study 7498689 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol-based electrolyte lavage solution (administered the day before colonoscopy)
Number of subjects: 200
Study 1452890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol-containing chewing gum
Number of subjects: 12
Study 1452890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-containing chewing gum
Number of subjects: 12
Study 1452890 — intervention group
Group type: COMPARATOR
Intervention: Control (1100-ppm-F NaF dentifrice)
Number of subjects: 12
Study 6231863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute sulfuric acid containing sodium sulfate (solution A)
Number of subjects: 40
Study 6231863 — intervention group
Group type: COMPARATOR
Intervention: 37% phosphoric acid (control)
Number of subjects: 40
Study 6231863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute sulfuric acid with 10% phosphoric acid (solution B)
Number of subjects: 40
Study 31167892 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus Saxagliptin (DAPA + SAXA)
Number of subjects: 643
Study 31167892 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine (INS)
Number of subjects: 643
Study 28544600 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (30 mg/kg in 5 min)
Number of subjects: 250
Study 28544600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 26132306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycaemic load (LGL) diet
Number of subjects: 19
Study 26132306 — intervention group
Group type: COMPARATOR
Intervention: Low-fat (LF) diet
Number of subjects: 19
Study 24045525 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental techniques in transplant surgery
Number of subjects: 0
Study 24045525 — intervention group
Group type: COMPARATOR
Intervention: Established protocols in clinical practice
Number of subjects: 0
Study 21846692 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 15
Study 21846692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21846692 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs) with placebo
Number of subjects: 15
Study 21846692 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs) with rivastigmine
Number of subjects: 15
Study 19948449 — intervention group
Group type: COMPARATOR
Intervention: Upfront debulking surgery
Number of subjects: 0
Study 19948449 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval debulking surgery after neo-adjuvant chemotherapy
Number of subjects: 0
Study 16814954 — intervention group
Group type: COMPARATOR
Intervention: 68 Gy
Number of subjects: 553
Study 16814954 — intervention group
Group type: COMPARATOR
Intervention: 78 Gy
Number of subjects: 553
Study 14732183 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal intervention
Number of subjects: 37
Study 14732183 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention
Number of subjects: 37
Study 14732183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined universal and targeted interventions
Number of subjects: 37
Study 14732183 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 37
Study 11347660 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing a very hard gum
Number of subjects: 15
Study 11347660 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing a soft gum
Number of subjects: 15
Study 11347660 — intervention group
Group type: EXPERIMENTAL
Intervention: Empty chewing with no bolus
Number of subjects: 15
Study 9174971 — intervention group
Group type: EXPERIMENTAL
Intervention: NaO Li Su
Number of subjects: 100
Study 9174971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1556390 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to sprayed turf 1 hour after application with clothing (long pants, short-sleeved shirt, socks, closed footwear)
Number of subjects: 20
Study 1556390 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to sprayed turf 1 hour after application without clothing (shorts, short-sleeved shirt, barefoot)
Number of subjects: 20
Study 1556390 — intervention group
Group type: COMPARATOR
Intervention: Exposure to sprayed turf 24 hours after application
Number of subjects: 20
Study 2412069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin treatment for 9 months
Number of subjects: 42
Study 2412069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin therapy
Number of subjects: 42
Study 31277331 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) counselling and a coupon for 12 standardised free-of-charge sessions in a sports club
Number of subjects: 217
Study 31277331 — intervention group
Group type: COMPARATOR
Intervention: PA counselling and written material
Number of subjects: 217
Study 28869405 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Coach
Number of subjects: 126
Study 28869405 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (Memory Training Program)
Number of subjects: 126
Study 26741729 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 (GS)
Number of subjects: 261
Study 26741729 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 261
Study 26741729 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 261
Study 25355131 — intervention group
Group type: EXPERIMENTAL
Intervention: POWeR Tracker (accessed in weeks 1 and 3)
Number of subjects: 13
Study 25355131 — intervention group
Group type: COMPARATOR
Intervention: POWeR (Web-based intervention)
Number of subjects: 13
Study 25355131 — intervention group
Group type: EXPERIMENTAL
Intervention: POWeR Tracker
Number of subjects: 13
Study 22782201 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) algorithm followed
Number of subjects: 1759
Study 22782201 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin (PCT) algorithm overruled
Number of subjects: 1759
Study 20456486 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg acetylsalicylic acid daily for 7 days
Number of subjects: 13
Study 20456486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 18580590 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment on admission including medical and cognitive evaluations, physical function, nutritional status, and psychosocial adjustment.
Number of subjects: 48
Study 18580590 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression score
Number of subjects: 48
Study 18580590 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent activities of daily living
Number of subjects: 48
Study 18580590 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 48
Study 18580590 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Berg Balance Score
Number of subjects: 48
Study 18580590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental status score
Number of subjects: 48
Study 18580590 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Berg Balance Scale score
Number of subjects: 48
Study 18580590 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment and follow-up
Number of subjects: 48
Study 15698731 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 lymphadenectomy
Number of subjects: 213
Study 15698731 — intervention group
Group type: COMPARATOR
Intervention: D1 lymphadenectomy
Number of subjects: 213
Study 11834879 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 10
Study 11834879 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide 10 mg
Number of subjects: 10